Literature DB >> 24401210

LXR agonism improves TNF-α-induced endothelial dysfunction in the absence of its cholesterol-modulating effects.

Frank Spillmann1, Sophie Van Linthout2, Kapka Miteva2, Mario Lorenz3, Verena Stangl3, Heinz-Peter Schultheiss1, Carsten Tschöpe4.   

Abstract

Stimulation of the liver X receptor (LXR) is associated with anti-inflammatory and vascular-protective effects under hyperlipemic conditions. We examined whether LXR stimulation influences TNF-α-induced endothelial dysfunction under normolipemic conditions. Endothelium-dependent vasorelaxation of aortic rings was determined in an organ water bath. Human umbilical vein endothelial cells (HUVEC) were exposed to TNF-α (10 ng/ml) in the presence or absence of 5 μM of the LXR agonist T0901317 or GW3965 and changes in TNF-α-induced endothelial cell apoptosis, inflammation, oxidative stress, and NO metabolism were analyzed. T0901317 improved TNF-α-impaired endothelium-dependent relaxation of aortic rings in response to acetylcholine. T0901317 decreased the TNF-α-induced apoptosis and inflammation as indicated by a decrease in caspase 3/7 activity, VCAM-1 mRNA expression and subsequent mononuclear cell adhesion. Furthermore, T0901317 reduced the expression of the oxidative stress markers: AT1R, NOX4, and p22phox and normalized the TNF-α-induced NOX activity to basal levels. In line with the reduced AT1R expression, T0901317 impaired the Ang II responsiveness. T0901317 influenced NO metabolism as indicated by a decrease in TNF-α-upregulated arginase activity, a reversal of TNF-α-induced downregulation of argininosuccinate synthase mRNA expression and eNOS expression to basal levels and a raise in NO production. Furthermore, T0901317 decreased the TNF-α-induced superoxide and nitrotyrosine production, but did not upregulate the TNF-α-downregulated eNOS dimer/monomer ratio. Silencing of LXRβ, but not of LXRα, abrogated the anti-apoptotic effects of T0901317. We conclude that LXR agonism improves TNF-α-impaired endothelial function via its anti-apoptotic, anti-inflammatory, and anti-oxidative properties and its capacity to restore TNF-α-impaired NO bioavailability independent of its cholesterol-modulating effects.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Endothelial dysfunction; HUVEC; LXR; LXR agonist; Liver X receptor; NAD(P)H oxidase; NO; NOX; Nitric oxide; O(2)•; ROS; RXR; TNF; TNF-α; eNOS; endothelial nitric oxide synthase; human umbilical vein cells; nitric oxide; reactive oxygen species; retinoid X receptor; superoxide; tumor necrosis factor

Mesh:

Substances:

Year:  2013        PMID: 24401210     DOI: 10.1016/j.atherosclerosis.2013.10.001

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  Lymphocytes from intermittent hypoxia-exposed rats increase the apoptotic signals in endothelial cells via oxidative and inflammatory injury in vitro.

Authors:  Hengjuan Guo; Jie Cao; Jinna Li; Xiaoyan Yang; Junnan Jiang; Jing Feng; Shuo Li; Jing Zhang; Baoyuan Chen
Journal:  Sleep Breath       Date:  2015-02-01       Impact factor: 2.816

2.  Canonical Wnt signaling induces vascular endothelial dysfunction via p66Shc-regulated reactive oxygen species.

Authors:  Ajit Vikram; Young-Rae Kim; Santosh Kumar; Asma Naqvi; Timothy A Hoffman; Ajay Kumar; Francis J Miller; Cuk-Seong Kim; Kaikobad Irani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-21       Impact factor: 8.311

3.  Previous physical exercise alters the hepatic profile of oxidative-inflammatory status and limits the secondary brain damage induced by severe traumatic brain injury in rats.

Authors:  Mauro Robson Torres de Castro; Ana Paula de Oliveira Ferreira; Guilherme Lago Busanello; Luís Roberto Hart da Silva; Mauro Eduardo Porto da Silveira Junior; Fernando da Silva Fiorin; Gabriela Arrifano; Maria Elena Crespo-López; Rômulo Pillon Barcelos; María J Cuevas; Guilherme Bresciani; Javier González-Gallego; Michele Rechia Fighera; Luiz Fernando Freire Royes
Journal:  J Physiol       Date:  2017-07-30       Impact factor: 5.182

Review 4.  Flow-mediated dilation and heart failure: a review with implications to physical rehabilitation.

Authors:  G P T Areas; A Mazzuco; F R Caruso; R B Jaenisch; R Cabiddu; S A Phillips; R Arena; A Borghi-Silva
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

5.  The liver X receptor agonist TO901317 protects mice against cisplatin-induced kidney injury.

Authors:  Meng Yang; Rong Wang; Jing Sun; Kezhou Yu; Bing Chen; Liang Xu; Bing Zhao; Haiping Wang
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-09

Review 6.  Arginase as a Critical Prooxidant Mediator in the Binomial Endothelial Dysfunction-Atherosclerosis.

Authors:  Luiza A Rabelo; Fernanda O Ferreira; Valéria Nunes-Souza; Lucas José Sá da Fonseca; Marília O F Goulart
Journal:  Oxid Med Cell Longev       Date:  2015-05-04       Impact factor: 6.543

Review 7.  APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective.

Authors:  Leon M Tai; Shivesh Ghura; Kevin P Koster; Vaiva Liakaite; Mark Maienschein-Cline; Pinal Kanabar; Nicole Collins; Manel Ben-Aissa; Arden Zhengdeng Lei; Neil Bahroos; Stefan J Green; Bill Hendrickson; Linda J Van Eldik; Mary Jo LaDu
Journal:  J Neurochem       Date:  2015-03-18       Impact factor: 5.372

Review 8.  New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction.

Authors:  Carsten Tschöpe; Sophie Van Linthout
Journal:  Curr Heart Fail Rep       Date:  2014-12

9.  Hyperglycemia Suppresses Calcium Phosphate-Induced Aneurysm Formation Through Inhibition of Macrophage Activation.

Authors:  Teruyoshi Tanaka; Yuichiro Takei; Dai Yamanouchi
Journal:  J Am Heart Assoc       Date:  2016-03-28       Impact factor: 5.501

Review 10.  Emerging role of liver X receptors in cardiac pathophysiology and heart failure.

Authors:  Megan V Cannon; Wiek H van Gilst; Rudolf A de Boer
Journal:  Basic Res Cardiol       Date:  2015-11-26       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.